ATRS Antares Pharma, Inc.

2.51
-0.04  -2%
Previous Close 2.55
Open 2.55
Price To book 9.55
Market Cap 389.59M
Shares 155,214,000
Volume 652,229
Short Ratio 2.39
Av. Daily Volume 1,326,120

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sNDA filing announced April 17, 2017. PDUFA date October 17, 2017 assuming 6-month priority review.
Makena - auto injector
Preterm birth
Approved December 8, 2011.
Anturol
Overactive bladder
Approved Oct 14, 2013.
OTREXUP
Rheumatoid arthritis (RA)
PDUFA date October 20, 2017.
VIBEX QuickShot
Testosterone deficiency

Latest News

  1. Edited Transcript of ATRS earnings conference call or presentation 9-May-17 12:30pm GMT
  2. ATRS: Milestones Continue to Align for Multiple 2018 Launches
  3. Antares Pharma Announces Poster Presentation at the American Urological Association Annual Meeting
  4. Antares Pharma reports 1Q loss
  5. Antares Pharma Reports First Quarter 2017 Operating and Financial Results
  6. Antares Pharma to Report First Quarter 2017 Financial and Operating Results and Host Webcast and Conference Call
  7. Antares Pharma to Present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference
  8. Don't Be Surprised If Dip Buyers Jump In on Any Pullback
  9. ETFs with exposure to Antares Pharma, Inc. : April 25, 2017
  10. AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use
  11. Antares Pharma Announces Poster Presentation of Quickshot Testosterone Data at the Endocrine Society Annual Meeting
  12. Penny Stocks to Watch for April 2017 (ATRS, WRN)
  13. ETFs with exposure to Antares Pharma, Inc. : March 27, 2017
  14. ATRS: 2016 Financial and Operational Results
  15. Antares Pharma, Inc. :ATRS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  16. Antares Pharma, Inc. :ATRS-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  17. Antares Pharma Inc. and Nivalis Therapeutics Inc. Show Resiliency as They Snap Back from Late 2016 Uncertainties
  18. Antares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results